Verizon posts higher subscriber loss on price hikes, competition
(Reuters) -Verizon Communications lost more wireless subscribers in the first quarter than Wall Street expected, as the U.S. telecom giant grappled with the fallout of recent price hikes and aggressive promotions from rivals.
The company warned in March that off-season promotions by AT&T and T-Mobile would result in "soft" subscriber growth, fueling fears about intensifying competition in an industry vying for a limited pool of new subscribers.
It also raised monthly prices for its customizable myPlan accounts with five lines or more by $3 per line, while customers on the New Verizon Plan faced a $4 per line increase for single mobile lines.
That led to a higher churn, percentage of customers exiting a service, with Verizon reporting a loss of 289,000 monthly bill-paying wireless subscribers in the first quarter, after it added a record 568,000 customers in the December quarter.
Analysts had expected the company to lose 166,400 subscribers, according to FactSet data.
The company introduced a three-year price guarantee in early April to lock in customers for its myPlan and myHome offerings.
It also reaffirmed its annual adjusted profit and free cash flow outlook, a sign it was confident in its business plans amid economic uncertainty.
In the first quarter, total revenue grew 1.5% to $33.5 billion, edging past analysts' estimates of $33.24 billion, according to data compiled by LSEG.
Wireless service revenue grew 2.7% to $20.8 billion, helped by the price hikes implemented by the company.
Verizon's consumer business added 137,000 wireless retail core prepaid customers, compared to 131,000 net losses a year ago, marking its best net additions since the acquisition of TracFone.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
22 minutes ago
- Fox News
iPhone
This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions. Legal Statement. Mutual Fund and ETF data provided by Refinitiv Lipper.
Yahoo
38 minutes ago
- Yahoo
May consumer prices rise moderately: Instant view
NEW YORK (Reuters) - U.S. consumer prices rose slightly in May as gasoline prices remained subdued, but inflation is likely to pick up in the months as tariffs boost the cost of imported goods. The consumer price index CPI increased 0.1% last month after rising 0.2% in April, the Labor Department said on Wednesday. Economists polled by Reuters had forecast the CPI would rise 0.2%. Year on year, the CPI climbed 2.4%, vs a 2.3% rise in the 12 months through April. Excluding the volatile food and energy components, the CPI rose 0.1% after gaining 0.2% in April. The so-called "core" CPI inflation increased 2.8% on a year-on-year basis in May after rising 2.8% in April. Inflation data has been slow to reflect U.S. President Donald Trump's slew of tariffs as retailers are selling merchandise that was built up before the levies took effect. MARKET REACTION: STOCKS: U.S. stock index futures erased earlier gains and were last up 18.5 points, or 0.31%, pointing to a modestly higher open on Wall Street BONDS: The 10-year U.S. Treasury yield fell 3.4 basis points to 4.44% while the two-year yield declined 5.9 basis points to 3.954% FOREX: The dollar index reversed modest gains and was off 0.26% to 98.71 while the euro was up 0.43% at $1.1472 COMMENTS: BRIAN JACOBSEN, CHIEF ECONOMIST, ANNEX WEALTH MANAGEMENT, MENOMONEE FALLS, WISCONSIN: "The post from Trump about the trade deal with China threatened to suck the air out of the importance of this CPI number. A 55% tariff on China does not seem like a good deal for households and businesses in America, but it was slightly better than the 60% tariff platform he campaigned on. "The CPI number was a lot tamer than expected. A lot of imported food items had relatively high inflation, like bananas rising 3.3% in price and toy prices rising 2.2%. Egg deflation is taking place with prices falling 2.7%. A little stability with trade policy could go a long way to help keep inflation from derailing. This is another example of why the Fed may shift its balance of risks to focusing more on growth threats than inflation threats." SLAWOMIR SOROCZYNSKI, HEAD OF FIXED INCOME, CROWN AGENTS INVESTMENT MANAGEMENT, LONDON: 'The CPI printing lower has been a relief. Now we need to clear the 10-year and 30-year Treasury auctions this week and then the market can switch into holiday mode.' GENNADIY GOLDBERG, HEAD OF US RATES STRATEGY, TD SECURITIES, NEW YORK 'The trade policy should still push inflation higher and that really feeds into the market reaction to this CPI print. I would say CPI came in notably better than expected for markets, with both headline and core surprising to the downside. Core goods were softer than expected, especially given weaker apparel prices. Core services were also relatively soft as well, with rents and OER coming in notably lower. 'All in all, this should drive a cautious bull steepening of the (Treasury) yield curve as investors pencil in more cuts. But there's still significant uncertainty around trade and investors know that that should push inflation higher in the months to come. It's a bit of stay of execution for the fixed income market for now.' WASIF LATIF, PRESIDENT AND CHIEF INVESTMENT OFFICER, SARMAYA PARTNERS, PRINCETON, NEW JERSEY 'It came in lower than consensus expected. So it's giving a little bit of a relief rally to the market, between equities rallying and bond yields coming down. But that's the initial reaction but we would see how it comes through over the next few days, weeks and until next month's print. "It's just one print and we have to take that into consideration and with a grain of salt and see how things pan out. There will continue to be impacts from things like tariffs and labor tightness because of immigration crackdown. "The other component is the energy piece. It did contribute a little better than expected numbers, with energy being down. And now this past month, you're seeing energy to hold its own and continue to grind higher so that also needs to be taken in consideration. "But net-net, it's a good number for this week and this month. It provides a little bit of relief. What's interesting is not only are you seeing equities jump here a little bit you're also seeing the US dollar decline because the markets is interpreting that it gives the Fed a little of a runway to reduce rates to the inflationary pressures that aren't there. The thing that is rallying the most on this news is gold.' (Compiled by the Global Finance & Markets Breaking News team) Sign in to access your portfolio
Yahoo
39 minutes ago
- Yahoo
Novo signs $812 million weight-loss drug license deal with US biotech Deep Apple
(Reuters) -Denmark's Novo Nordisk is partnering with biotech company Deep Apple Therapeutics in a deal worth up to $812 million to develop drugs for cardiometabolic diseases, including obesity, the California-based company said on Wednesday. Deep Apple discovers drug candidates using its AI-based platform that screens virtual libraries of billions of compounds to cut drug discovery time, the company said. Under the deal, Novo will receive exclusive global rights to develop and commercialize so-called non-incretin oral therapies, which belong to a different class of medicines than its popular weight-loss and diabetes drugs Wegovy and Ozempic. WHY IT'S IMPORTANT Novo has been trying to strengthen its foothold in the potential $150 billion weight-loss drug market through the development of next-generation treatments as well as acquisitions and partnerships. In March, the company signed two licensing deals and gained access to experimental obesity drugs from Lexicon Pharmaceuticals and China-based United Laboratories International. CONTEXT Novo in May ousted CEO Lars Fruergaard Jorgensen over concerns the Danish company - a world leader in the lucrative weight-loss drug market - was losing its first-mover advantage. The company's shares have plunged since hitting a record high in June last year as competition, particularly from U.S. rival Eli Lilly, eats into its market share, while Novo's pipeline of new drugs has failed to impress investors. BY THE NUMBERS As part of the license agreement with Novo, Deep Apple will be eligible to receive up to $812 million in payments, as well as potential royalties on sales of any products that emerge from their collaboration.
